2025-11781RuleWallet

FDA Assigns a Newborn Screening Test to Class II

Published Date: 6/26/2025

Rule

Summary

The FDA is officially putting the lysosomal storage disorder newborn screening test system into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and effective while speeding up access to new, helpful devices for babies. The new rules took effect on June 26, 2025, making it simpler and less costly for companies to bring these lifesaving tests to hospitals.

Analyzed Economic Effects

3 provisions identified: 3 benefits, 0 costs, 0 mixed.

Newborn Screening Tests Reclassified to Class II

The FDA officially classified the lysosomal storage disorder newborn screening test system as Class II (special controls) effective June 26, 2025, with the classification applicable on February 3, 2017. The device is subject to premarket notification under section 510(k), and FDA states this will reduce regulatory burdens and help speed patient access to these tests.

Required Clinical Studies and Lab Performance Rules

Manufacturers must perform clinical validation using well-characterized clinical specimens from the intended newborn population and testing by representative operators, and must demonstrate things like reference intervals, limit of detection/quantitation, carryover/drift, and imprecision. The rule requires imprecision studies using sample panels from at least three reagent lots and at least three instruments over more than 20 testing days, and prohibits reporting sample concentrations below the limit of quantitation.

Labeling Must Disclose Limits and Error Rates

Labeling for these tests must include a warning that the test is not intended to diagnose lysosomal storage disorders and must state that results should be used with other clinical findings and confirmed by alternative methods. Labels must also include detailed device performance data from the clinical study, including the false positive rate, the false negative rate, and performance in relevant subgroups (for example: age at collection, birth weight, sex, gestational age, race, ethnicity).

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
6/26/2025
6/26/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register